
(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) announced a significant milestone with a USD 1.25 million payment triggered by the robust sales performance of its antifungal medication, Cresemba® (isavuconazole), in the Asia Pacific region and China by its license partner … Read the full press release